Structure Therapeutics
Structure Therapeutics Inc is an American clinical-stage biopharmaceutical company focused on developing orally available small molecule therapeutics for metabolic and pulmonary diseases. The company utilizes its proprietary structure-based drug discovery platform to engineer oral G-protein coupled receptor therapeutics, including lead candidate GSBR-1290, an oral GLP-1 receptor agonist for obesity and type 2 diabetes. Main revenue drivers currently stem from investment capital financing, research collaborations, and potential development milestones as clinical trials progress. Structure Therapeutics targets endocrinologists, clinical research networks, biopharmaceutical partners, and metabolic disease patients in North America and global markets. The company holds an innovative position in oral small molecule GLP-1 and GPCR drug discovery. Headquartered in South San Francisco, California, it is listed on the Nasdaq Stock Market.
5 of the funds FundTelligence covers report a position in Structure Therapeutics.
- Legal name
- Structure Therapeutics Inc
- Sector
- Health Care
- Country
- United States
- Funds holding it
- 5
- Exposure themes
- Incretin & GLP-1 Therapies, Obesity, Obesity & Metabolic Health
Funds holding Structure Therapeutics
- DNB Bioteknologi — DNB · 1.15 % (full portfolio disclosed, September 2026)
- SEB Läkemedelsfond — SEB · 0.73 % (full portfolio disclosed, June 2026)
- Franklin Biotechnology Discovery Fund — Franklin Templeton · 0.35 % (full portfolio disclosed, September 2026)
- BlackRock iShares NASDAQ US Biotechnology UCITS ETF — BlackRock · 0.11 % (full portfolio disclosed, October 2026)
- Handelsbanken Global SMB Index Criteria — Handelsbanken · 0.02 % (full portfolio disclosed, October 2026)